

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY

RONALD D. HOOD^{1,2} AND ROBERT M. PARKER³

¹*Ronald D. Hood & Associates, Toxicology Consultants, Tuscaloosa, Alabama*

²*The University of Alabama, Tuscaloosa, Alabama*

³*Hoffmann-LaRoche Inc., Nutley, New Jersey*

Contents

- 1 Regulatory Agency Guidance
- 2 Flexibility in Developing a Testing Strategy
- 3 Fertility and General Reproductive Performance Study (Segment I)
 - 3.1 Rationale for the Test
 - 3.2 Male-Only, Female-Only, and Combined Segment I Studies
 - 3.3 Animal Species and Strain Selection
 - 3.4 Procurement and Acclimation of the Test Animals
 - 3.5 Selection of Dosage Groups, Controls, and Route of Administration
 - 3.6 Treatment Timing and Test Duration
 - 3.7 Mating Procedures, Detection of Mating, and Housing of Mated Females
 - 3.8 In-Life Observations: Parental Body Weight, Feed Consumption, Estrous Cycles, and Clinical Signs
 - 3.9 Female Reproductive Evaluation
 - 3.10 Male Reproductive Evaluation
 - 3.11 Analysis of Fertility Data
 - 3.12 Interpretation of the Data
- 4 Prenatal Development Toxicity Study (Segment II)
 - 4.1 Rationale for the Test
 - 4.2 Dose Range-Finding Study
 - 4.3 The Definitive Study
 - 4.4 Interpretation of the Data
 - 4.5 Reporting the Results of Developmental Toxicity Studies
- 5 Perinatal and Postnatal Study (Segment III)
 - 5.1 Rationale for the Test
 - 5.2 Animal Species and Strain Selection

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing

Edited by Shayne C. Gad

Copyright © 2010 John Wiley & Sons, Inc.